I would like to do a research on how Chronic Stress influence on Cancer Genetically.
Chronic Stress Activates Hormonal Responses
•
Chronic stress triggers the hypothalamic-pituitary-adrenal (HPA) axis.
•
This leads to increased cortisol (the “stress hormone”) and other stress hormones like adrenaline.
•
Impact: High cortisol over time suppresses immune surveillance — your body’s ability to detect and destroy abnormal cells decreases.
Stress Leads to Chronic Inflammation
•
Stress hormones can increase pro-inflammatory molecules (like cytokines).
•
Chronic inflammation creates an environment that promotes DNA damage and cell proliferation.
•
Impact: Mutated cells are more likely to survive and multiply instead of being eliminated.
Epigenetic Modifications
•
Chronic stress can change how genes are expressed without altering the DNA sequence.
•
Mechanisms include:
o
DNA methylation → silences tumor suppressor genes (e.g., TP53, BRCA1)
o
Histone modification → changes how DNA is packaged, affecting gene activity
•
Impact: Genes that normally prevent cancer may be “turned off,” increasing vulnerability.
DNA Damage and Impaired Repair
•
Stress can interfere with DNA repair mechanisms, meaning mutations accumulate faster.
•
Cells with damaged DNA that aren’t repaired can transform into cancerous cells.
•
Impact: Genetic instability in breast tissue increases cancer risk.
Interaction with Genetic Susceptibility
•
People with BRCA1/2 mutations or other cancer-related genes are more sensitive to these mechanisms.
#Chronic_Stress Activates Hormonal Responses#Stress_Leads to Chronic Inflammation#Epigenetic_Modifications#DNA_Damage and Impaired Repair#Interaction_with Genetic Susceptibility
1. Analyze and model endocrine–immune signaling networks by which chronic stress promotes oncogenesis, integrating HPA-axis glucocorticoid and β-adrenergic signaling with inflammatory transcriptional programs using pathway databases, transcription factor activity inference, and dynamic network modeling.
Learning Targets:
1. Map HPA and sympathetic cascades to tumor and microenvironment targets using KEGG, Reactome, and OmniPath; construct a directed, signed multi-layer interaction graph in Cytoscape including receptor–effector mappings.
2. Infer GR, NF-κB, STAT3, and AP-1 activities from bulk or single-cell transcriptomes using PROGENy/DoRothEA/VIPER and benchmark against perturbational controls (e.g., LINCS L1000).
3. Quantify chronic stress biomarker profiles by fitting mixed-effects models to diurnal cortisol (AUCg, CAR, slope) and HRV metrics; measure catecholamines via LC–MS/MS and derive a latent stress score using factor analysis.
4. Conduct a systematic review and random-effects meta-analysis of GR/β-AR activation effects on inflammatory signaling, estimating pooled effect sizes, heterogeneity (I2), and small-study bias.
5. Construct a causal DAG linking stress mediators to oncogenic outcomes, specify testable conditional independencies, and identify minimally sufficient adjustment sets for downstream analyses.
Modules
1. Endocrine–Immune Signaling Landscape for Oncogenesis
1. 1. Map HPA and Sympathetic Cascades to Tumor and Microenvironment Targets
Learning Outcomes:
1. Extract HPA-axis and sympathetic pathway reactions from KEGG, Reactome, and OmniPath and compile receptor–ligand–effector mappings for GR (NR3C1) and β-adrenergic receptors (ADRB1/2/3).
2. Construct a directed, signed multi-layer graph in Cytoscape encoding activation/inhibition edges and tissue/cell-type layers for tumor cells, immune populations, stroma, and vasculature.
3. Annotate nodes with UniProt identifiers, post-translational modification states, and subcellular localization and validate edge direction/sign with primary literature citations.
4. Integrate cytokine and chemokine signaling modules (NF-κB, STAT3, AP-1) and connect endocrine inputs to inflammatory transcriptional outputs with receptor–effector chains.
5. Implement versioned data provenance and edge-confidence scoring using literature evidence counts and database source weights and export to NDEx.
6. Evaluate graph completeness by computing coverage of curated GR/β-AR target sets and report prioritized gaps requiring manual curation.
1. 2. Dynamic Network Modeling of Stress–Inflammation Crosstalk
Learning Outcomes:
1. Formulate ODE or rule-based models capturing GR/β-AR–NF-κB/STAT3 cross-talk and specify parameters from literature priors or data-driven estimates.
2. Fit models to time-series phospho-protein or transcript readouts under cortisol/epinephrine stimulation using nonlinear least squares or Bayesian inference and quantify fit (NRMSE, MAE).
3. Perform local and global sensitivity analyses (PRCC, Sobol indices) to rank parameters governing inflammatory outputs and TF activities.
4. Simulate pharmacologic perturbations (propranolol, mifepristone) and predict changes in downstream TF activity profiles and cytokine secretion.
5. Validate model predictions against independent datasets and compute prediction intervals with coverage probabilities.
6. Document model assumptions, parameter priors, and export SBML/SED-ML packages with reproducible simulation scripts.
1. 3. Calibrate Edge Weights and Uncertainty in Stress–Inflammation Networks
Learning Outcomes:
1. Extract quantitative kinetic parameters from primary studies and phospho-protein time courses to assign prior weights for GR/β-AR to NF-κB/STAT3/AP-1 edges.
2. Implement Bayesian evidence synthesis to combine literature priors and dataset-specific estimates and compute posterior edge weight distributions with credible intervals.
3. Execute bootstrapped graph resampling and edge-dropping analyses to quantify network robustness and identify brittle or non-identifiable connections.
4. Compare alternative network topologies using cross-validated likelihood, WAIC/LOOIC, and predictive accuracy metrics and select parsimonious models.
5. Validate edge directionality with perturbational datasets (e.g., GR agonists/antagonists, β-AR modulators) and compute causal consistency scores.
6. Export weighted, uncertainty-annotated networks to NDEx/SBML and document calibration decisions, data sources, and versioned provenance.
2. Transcriptional Activity Inference and Perturbational Benchmarking
2. 1. Infer GR and Inflammatory TF Activities from Bulk/Single-Cell Transcriptomes
Learning Outcomes:
1. Process bulk and single-cell RNA-seq to normalized matrices (TPM/CPM/log-normalized) and implement batch correction where appropriate (ComBat, Harmony).
2. Infer TF activities for GR, NF-κB, STAT3, and AP-1 using DoRothEA/VIPER and pathway activities via PROGENy and quantify activity effect sizes.
3. Benchmark inferred activities against curated GR target signatures and known pathway activation states from reference datasets.
4. Quantify uncertainty via bootstrapping or jackknife resampling and construct confidence intervals for TF activity scores.
5. Compare activity distributions across cell types or conditions using appropriate mixed models and multiplicity control.
6. Publish reproducible pipelines with fixed seeds, parameter settings, and environment manifests.
2. 2. Benchmark Activity Inference with LINCS and Perturbational Controls
Learning Outcomes:
1. Retrieve LINCS L1000 profiles for GR agonists/antagonists and β-AR modulators and harmonize gene identifiers and signatures.
2. Compute similarity between inferred activity signatures and LINCS perturbational signatures using GSEA/NES and rank correlation metrics.
3. Evaluate method performance using precision–recall and ROC against gold-standard perturbations and report AUROC/AUPRC with CIs.
4. Optimize regulon confidence thresholds and gene set choices to maximize external validation metrics while controlling FDR.
5. Implement negative controls and permutation tests to assess small-study bias and batch confounding in benchmarking.
6. Summarize benchmarking in transparent reports including dataset characteristics, metrics, and sensitivity analyses.
2. 3. Cross-Platform Integration and Robust TF Activity Estimation
Learning Outcomes:
1. Harmonize bulk microarray, bulk RNA-seq, and single-cell datasets using gene identifier mapping and batch mitigation (ComBat, Harmony) and quantify residual batch effects with kBET/LISI.
2. Tune DoRothEA regulon confidence thresholds and execute VIPER with stability selection; compute intra-class correlation coefficients for TF activity reproducibility across platforms.
3. Conduct random-effects meta-analysis of GR/NF-κB/STAT3/AP-1 activity effects across studies and estimate heterogeneity (I2) with sensitivity to regulon choices.
4. Assess robustness of TF activity inference to gene dropout and depth using downsampling, imputation, and noise injection; set minimum data-quality thresholds.
5. Correlate TF activity scores with orthogonal phospho-proteomics and cytokine secretion readouts and compute concordance with confidence intervals.
6. Package cross-platform pipelines in containers and publish benchmark datasets, parameter files, and reproducible notebooks.
3. Stress Biomarker Quantification and Causal Graph Design
1. Design diurnal cortisol sampling schedules and compute AUCg, CAR, and diurnal slope; extract HRV metrics (RMSSD, HF power) and quantify catecholamines via LC–MS/MS.
2. Fit mixed-effects models estimating diurnal cortisol metrics and HRV differences while adjusting for age, sex, collection time, and batch effects.
3. Construct a latent stress factor using exploratory/confirmatory factor analysis and evaluate model fit (CFI/TLI >0.95, RMSEA <0.06).
4. Harmonize biomarker units across cohorts, apply QC thresholds, and flag outliers using robust statistics.
5. Compute intra-class correlation and week-to-week stability to assess biomarker reliability and feasibility for longitudinal studies.
6. Generate a composite stress score and stratify participants into quantiles for downstream association modeling.
3. 2. Construct Causal DAGs and Identify Adjustment Sets
Learning Outcomes:
1. Draft a causal DAG linking stress biomarkers, GR/β-AR activities, inflammatory TFs, and oncogenic outcomes including confounders (SES, comorbidities) and mediators.
2. Derive testable conditional independencies and design falsification tests using negative controls or instrumental variables where feasible.
3. Identify minimally sufficient adjustment sets using dagitty and justify inclusion/exclusion decisions in a design table.
4. Specify data collection plans and measurement timing to satisfy backdoor criteria and minimize collider bias.
5. Preregister DAGs and corresponding statistical analysis plans with clearly defined estimands and sensitivity analyses.
6. Communicate DAG assumptions and limitations to collaborators and refine based on expert feedback.
3. 3. Simulate and Stress-Test DAG-Informed Analyses
Learning Outcomes:
1. Generate synthetic datasets consistent with proposed DAGs using structural equation models and vary confounding strengths and mediator effects to probe identifiability.
2. Verify conditional independencies with partial correlation and conditional mutual information tests and report deviations indicating model misspecification.
3. Evaluate candidate adjustment sets via d-separation and quantify bias introduced by collider stratification through simulation experiments.
4. Conduct power analyses for associations and mediation effects given biomarker variability, sampling frequency, and anticipated effect sizes.
5. Implement negative control simulations to calibrate Type I error under exposure/mediator misclassification and missingness mechanisms.
6. Archive simulation code, parameter grids, and preregistered decision rules to ensure transparent analytic planning.
2. Execute and interpret multi-omic epigenomic profiling of stress-induced gene regulation using DNA methylation assays (WGBS/RRBS or EPIC), chromatin accessibility (ATAC-seq), and GR/histone mark ChIP-seq or CUT&Tag, integrated with RNA-seq data.
Learning Targets:
1. Generate and QC methylation, ATAC-seq, and GR/CUT&Tag or ChIP-seq datasets meeting thresholds (bisulfite conversion >99%, duplication <15%, ATAC TSS enrichment >7, FRiP >0.2, IDR <0.05) and document batch structure.
2. Perform differential methylation (Bismark/DSS or DMRcate), accessibility (MACS2/ArchR), and peak calling for ChIP/CUT&Tag; control FDR <0.05 with covariate adjustment (batch, cell cycle).
3. Integrate epigenomic layers with RNA-seq (DESeq2/edgeR, limma-voom), link peaks to genes (ChIPseeker/Signac), conduct motif enrichment (HOMER/MEME), and infer GR cofactor networks.
4. Validate priority loci via targeted bisulfite pyrosequencing, CUT&Tag qPCR, and RT–qPCR, and report absolute methylation differences, fold changes, and 95% confidence intervals.
5. Reproduce analyses with containerized Snakemake or Nextflow workflows and publish executable notebooks (R Markdown/Jupyter) with complete provenance and checksums.
Modules
1. Epigenomic Assay Design and Quality Control
1. 1. Plan and Generate DNA Methylation and Chromatin Accessibility Datasets
Learning Outcomes:
1. Design sampling, choose WGBS/RRBS vs EPIC based on coverage, cost, and hypothesis, and randomize across batches to mitigate confounding.
2. Execute library preparation with spike-in controls and achieve bisulfite conversion efficiency >99% with documented QC.
3. Sequence to target depth and compute duplication rates <15%, coverage uniformity, and conversion rates with MultiQC outputs.
4. Align reads and call methylation with Bismark; generate per-sample QC reports and flag samples failing pre-defined thresholds.
5. Document batch structure, technical replicates, and metadata according to MIAME/MINSEQE standards.
6. Establish data acceptance criteria and remediation steps and track decisions in a QC dashboard.
1. 2. GR CUT&Tag/ChIP-seq and ATAC-seq Best Practices
Learning Outcomes:
1. Optimize GR CUT&Tag or ChIP-seq (antibody validation, spike-ins) to achieve FRiP >0.2 and replicate concordance (IDR <0.05).
2. Perform ATAC-seq with TSS enrichment >7 and nucleosomal banding patterns; quantify library complexity and mitochondrial reads.
3. Call peaks with MACS2 using appropriate controls and blacklist filtering; document parameters and versions.
4. Assess replicate concordance using IDR and remove low-confidence peaks; annotate peaks with genomic features.
5. Aggregate QC metrics (FRiP, IDR, TSS enrichment, duplication) into assay-specific dashboards for review.
6. Archive raw FASTQ, BAM, peak files, and metadata with checksums and accession-ready annotations.
1. 3. Design Against Batch and Confounding in Epigenomic Experiments
Learning Outcomes:
1. Randomize samples across sequencing lanes, plates, and library preparation batches and construct design matrices balancing key covariates (age, sex, cell type).
2. Implement blocking, technical replicates, and spike-in strategies; compute design efficiency and expected variance reduction.
3. Simulate batch effects and covariate imbalance to estimate their impact on DMR/DAR detection power and choose target sample sizes.
4. Apply normalization strategies (e.g., RLE/TMM for counts, spike-in scaling for ChIP/CUT&Tag) and evaluate between-batch variability reductions.
5. Define QC stopping rules, remediation pathways (re-sequencing, sample exclusion), and decision logs for deviations.
6. Compile an experimental design dossier documenting randomization, blinding, and batch-control procedures for pre-registration.
2. Differential Analysis and Multi-omic Integration
2. 1. Detect Differential Methylation and Accessibility
Learning Outcomes:
1. Call DMRs with DSS or DMRcate using covariate-adjusted models and control FDR <0.05 with Benjamini–Hochberg procedures.
2. Identify differential accessibility with ArchR or DESeq2 while adjusting for batch and cell cycle effects in design formulas.
3. Annotate DMRs and DARs to genes, promoters, enhancers, and CpG features using ChIPseeker and annotatePeaks.
4. Compute effect sizes (absolute methylation difference, log2FC accessibility) and 95% confidence intervals and visualize volcano/MA plots.
5. Perform enrichment of genomic annotations and repeats to contextualize epigenomic changes and test enrichment significance.
6. Cross-validate findings across platforms (RRBS vs WGBS) and replicate cohorts to assess robustness.
2. 2. Integrate Epigenomic Layers with RNA-seq and Motif Analysis
Learning Outcomes:
1. Integrate ATAC, methylation, and GR peak data with RNA-seq DE genes using peak-to-gene linkage and correlation approaches (ArchR, Signac).
2. Conduct motif enrichment with HOMER/MEME, identify GR cofactors (e.g., FOXA1, JUN), and compute motif deviation scores.
3. Assemble cis-regulatory networks linking enhancers to target genes using co-accessibility and TF motif evidence.
4. Prioritize enhancer–promoter interactions supported by multi-omic concordance and quantify regulatory impact on expression.
5. Evaluate concordance between GR occupancy changes and expression of target genes under stress-hormone exposure.
6. Produce integrative figures (track plots, co-accessibility networks) and narrative summaries suitable for manuscripts.
2. 3. Incorporate 3D Genome and QTL Evidence into Regulatory Models
Learning Outcomes:
1. Integrate Hi-C/HiChIP/PLAC-seq contact maps to connect distal regulatory elements to putative target genes in stress-responsive regions.
2. Perform colocalization analyses with eQTL/caQTL datasets using COLOC or eCAVIAR and interpret posterior probabilities for shared causal variants.
3. Prioritize regulatory variants that modulate GR occupancy or enhancer accessibility and link them to stress-induced gene expression changes.
3. Validation and Reproducible Epigenomics
3. 1. Targeted Validation of Priority Loci
Learning Outcomes:
1. Design bisulfite pyrosequencing assays for top DMRs including internal controls and validate assay specificity and sensitivity.
2. Execute targeted methylation validation and compute absolute methylation differences with 95% confidence intervals.
3. Perform CUT&Tag qPCR at selected peaks to confirm occupancy and report fold enrichment over input with error estimates.
4. Validate expression changes for candidate genes using RT–qPCR and compute fold change with confidence intervals.
5. Assess technical and biological replication and evaluate effect robustness across conditions and donors.
6. Document validation SOPs, acceptance thresholds, and results in a standardized report.
3. 2. Reproducible Workflows and Provenance
Learning Outcomes:
1. Containerize pipelines with Snakemake or Nextflow, pin software versions, and define resources for each rule/process.
2. Implement automated CI checks and data integrity validations; capture provenance with RO-Crate or W3C PROV.
3. Publish executable notebooks (R Markdown/Jupyter) with parameterized runs and fixed random seeds.
4. Generate checksums for all inputs/outputs and create searchable data dictionaries linking files to metadata.
5. Reproduce full analyses on clean environments (Docker/Singularity) and log deviations with justifications.
6. Release code, workflows, and processed data with DOIs and permissive licenses, documenting reuse instructions.
3. 3. Cross-Lab Reproducibility and Benchmarking Exercises
Learning Outcomes:
1. Coordinate multi-lab benchmarking using shared reference samples and harmonized SOPs and define acceptance criteria for concordance.
2. Quantify inter-lab reproducibility with ICC, Pearson/Spearman correlations, and IDR across peak sets and DMR calls.
3. Implement blinded data exchange and independent reanalysis to assess pipeline portability and analyst effects.
4. Compare alternative aligners, peak callers, and DMR algorithms using standardized truth sets and evaluate precision/recall and calibration.
3. Quantify DNA damage, repair pathway function, replication stress, and genomic instability under stress-hormone exposure using comet assays, DNA damage foci imaging, HR/NHEJ reporter systems, DNA fiber assays, and mutational signature analysis from WGS/WES.
Learning Targets:
1. Expose relevant cell models to cortisol and/or catecholamines and measure DNA strand breaks by alkaline and neutral comet assays, computing olive tail moment and percent tail DNA versus vehicle controls.
2. Image and quantify γ-H2AX, 53BP1, and RAD51 foci kinetics following genotoxic challenge, estimate repair half-lives using nonlinear mixed-effects models, and compare stressed versus control conditions.
3. Assess homologous recombination and non-homologous end joining efficiencies with DR-GFP and EJ5-GFP reporters and quantify replication stress using DNA fiber assays (fork speed, stall rate) and EdU incorporation.
4. Call somatic SNVs/indels (Mutect2/Strelka2) and structural variants (Manta/GRIDSS), compute HRD scores (LOH, LST, TAI), and estimate telomere length (qPCR/Flow-FISH).
5. Extract mutational signatures (SigProfiler/MutationalPatterns) and attribute oxidative damage (e.g., SBS18/36) or replication-stress patterns, comparing mutation burdens and signature exposures across stress conditions.
Modules
1. Stress Exposure and DNA Damage Quantification
1. 1. Design Hormone Exposure and Comet Assays
Learning Outcomes:
1. Culture relevant models and expose to cortisol/catecholamines with dose–time matrices; record media conditions and viability.
2. Execute alkaline and neutral comet assays and quantify olive tail moment and percent tail DNA using standardized analysis pipelines.
3. Calibrate assays with positive controls (e.g., H2O2) and generate standard curves to validate dynamic range.
4. Compare stressed versus vehicle conditions using mixed-effects models accounting for plate/batch effects and compute effect sizes with CIs.
5. Implement QC criteria (cell count thresholds, electrophoresis time limits) and document exclusions transparently.
6. Archive raw images, analysis scripts, and summary statistics with traceable identifiers.
1. 2. Quantify DNA Damage Foci and Repair Kinetics
Learning Outcomes:
1. Stain γ-H2AX, 53BP1, and RAD51 foci and image at multiple time points following genotoxic challenge under stress and control conditions.
2. Fit nonlinear mixed-effects models to foci kinetics to estimate repair half-lives and confidence intervals.
3. Contrast repair rates between stressed and control groups and compute adjusted mean differences with multiplicity control.
4. Validate antibody specificity and imaging parameters (exposure, z-stacks) and implement blinded analysis.
5. Automate foci counting with validated pipelines (CellProfiler/FIJI) and perform QA on batch variability.
6. Summarize kinetics and model diagnostics in reproducible reports for peer review.
1. 3. Quantify Oxidative Damage and Antioxidant Responses Under Hormone Exposure
Learning Outcomes:
1. Measure oxidative DNA damage (8-oxo-dG) using LC–MS/MS or ELISA with calibrated standards and report absolute quantities with CIs.
2. Quantify cellular ROS with DCFDA and mitochondrial superoxide with MitoSOX by flow cytometry or microscopy and establish gating/thresholds.
3. Assess NRF2-mediated antioxidant responses via qPCR or western blot (e.g., NQO1, HMOX1) and compute fold changes with error estimates.
4. Model dose–response relationships between cortisol/epinephrine and oxidative markers using nonlinear regression and estimate EC50/IC50 values.
5. Test antioxidant or receptor-blockade interventions for rescue of oxidative damage and report standardized effect sizes with multiplicity control.
6. Link oxidative damage metrics to comet outcomes using mediation or SEM frameworks and document assumptions and robustness checks.
2. Repair Pathway Function and Replication Stress
2. 1. Quantify HR and NHEJ Using Reporter Systems
Learning Outcomes:
1. Introduce DR-GFP and EJ5-GFP reporters, induce DSBs, and quantify HR/NHEJ efficiencies via flow cytometry with appropriate controls.
2. Modulate GR/β-AR signaling pharmacologically or via CRISPRi/a (NR3C1, ADRB2) and measure effects on repair pathway usage.
3. Control for cell cycle distribution and viability using EdU/PI and include these covariates in statistical models.
4. Analyze reporter outcomes with linear/mixed models and adjust for multiple comparisons across conditions.
5. Compute z-scores relative to vehicle controls and derive standardized effect sizes with 95% CIs.
6. Version-control FCS files, gating strategies, and analysis scripts for reproducibility.
2. 2. Assess Replication Stress with DNA Fiber Assays
Learning Outcomes:
1. Label replication forks with CldU/IdU, prepare DNA fibers, and image to quantify fork speed, stall rate, and origin firing under stress hormones.
2. Implement blinded measurement and QC of fiber tract lengths and discard artifacts by pre-registered rules.
3. Quantify replication stress via EdU incorporation and checkpoint markers (pRPA, pCHK1) and integrate with fiber metrics.
4. Evaluate pharmacologic rescue (e.g., propranolol/mifepristone) on replication stress phenotypes and compute effect sizes.
5. Model replication metrics using appropriate error structures and test for hormone–treatment interactions.
6. Integrate replication stress readouts with DNA damage and repair metrics to infer mechanistic links.
2. 3. Profile DNA Damage Response Signaling and Checkpoints
Learning Outcomes:
1. Quantify DDR checkpoint activation (pATM, pATR, pCHK1/2) by western blot or phospho-flow over time following hormone exposure and genotoxic challenge.
2. Integrate DDR signaling dynamics with HR/NHEJ reporter efficiencies using regression or SEM to infer pathway dependencies under stress.
3. Perturb DDR nodes (ATM/ATR/CHK inhibitors) and quantify changes in repair pathway choice; compute interaction contrasts and confidence intervals.
3. Genomic Instability and Mutational Signatures
3. 1. Somatic Variant Calling and HRD Profiling
Learning Outcomes:
1. Call somatic SNVs/indels with Mutect2/Strelka2, apply artifact filters, and estimate tumor purity and ploidy where applicable.
2. Detect structural variants with Manta/GRIDSS and annotate breakpoints with gene impact and repeat content.
3. Compute HRD scores (LOH, LST, TAI) and integrate copy number profiles to assess homologous recombination deficiency.
4. Estimate telomere length via qPCR or Flow-FISH and compare across stress conditions with adjusted models.
5. Correlate genomic instability metrics with stress exposure intensity and biomarker levels to test dose–response relationships.
6. Prepare variant callsets and HRD summaries for downstream mutational signature extraction with full provenance.
3. 2. Extract and Interpret Mutational Signatures
Learning Outcomes:
1. Extract mutational signatures using SigProfiler or MutationalPatterns with bootstrap stability assessments and reconstruction error metrics.
2. Attribute oxidative damage (SBS18/36) or replication-stress signatures and quantify exposures with confidence intervals.
3. Compare signature exposures across stress and control conditions and test differences with multiplicity-adjusted p-values.
4. Link signature exposures to measured repair defects and replication stress metrics using regression or SEM.
5. Assess attribution uncertainty via perturbation analyses and sensitivity to reference signature choices.
6. Publish code and reports detailing signature solutions, diagnostics, and biological interpretations.
3. 3. Conduct Longitudinal Evolution Experiments Under Chronic Stress
Learning Outcomes:
1. Design long-term culture or organoid evolution experiments with intermittent hormone exposure and define passage schedules and population bottlenecks.
2. Sequence WGS/WES at predefined passages; implement barcoding or clonal tracking to control for clonal sweeps and drift.
3. Model mutation accumulation rates and spectrum shifts using Poisson/negative binomial regression with offset for callable genome and coverage.
4. Design and implement preclinical models to test causal links between chronic stress and tumor progression, including validated stress paradigms and pharmacologic or genetic modulation of GR/β-adrenergic signaling, with rigorous design, analysis, and ethics compliance.
Learning Targets:
1. Specify chronic stress protocols (e.g., restraint, social defeat, CUMS) with biomarker validation (corticosterone, HRV telemetry, behavioral assays) and preregister hypotheses and outcomes.
2. Conduct power and sample size calculations using pilot variance and tumor growth kinetics, implement randomization and blinding, and define a priori statistical analysis plans.
3. Implement intervention arms (propranolol, mifepristone, CRHR1 antagonists; CRISPRi/a of NR3C1/ADRB2) and quantify effects on tumor burden, metastasis, and immune infiltration via flow cytometry and IHC.
4. Analyze longitudinal tumor growth and metastasis using mixed-effects or joint models, adjust for cage and batch effects, and control multiplicity for multi-endpoint testing.
5. Ensure IACUC/ARRIVE/PREPARE compliance, monitor animal welfare with predefined humane endpoints, and version-control protocols and data (Git/OSF) with complete deviation logs.
6. Develop and critique preclinical case vignettes comparing stress paradigms and intervention strategies across at least two tumor models; predefine success criteria, perform blinded outcome re-review, and document generalizability and threats to validity.
Modules
1. Validated Stress Paradigms and Preregistration
1. 1. Implement Chronic Stress Protocols with Biomarker Validation
Learning Outcomes:
1. Specify restraint, social defeat, or CUMS paradigms with durations, schedules, and environmental controls to minimize confounding.
2. Validate stress induction via corticosterone assays, HRV telemetry, and behavioral readouts (elevated plus maze) with predefined thresholds.
3. Standardize housing, handling, and enrichment procedures and document deviations and corrective actions.
4. Define humane endpoints and monitoring schedules consistent with IACUC and ARRIVE guidelines.
5. Train personnel using checklists and conduct pilot runs to calibrate procedures and variability.
6. Record protocol adherence, biomarker compliance, and adverse events in auditable logs.
1. 2. Preregister Hypotheses, Outcomes, and Analytical Plans
Learning Outcomes:
1. Preregister hypotheses, primary/secondary endpoints, and statistical plans on OSF or equivalent with time-stamped versions.
2. Define inclusion/exclusion criteria and randomization schemes a priori and store seed values for reproducibility.
3. Calibrate biomarker assays (corticosterone, HRV) and predefine thresholds for protocol success/failure.
4. Construct case report forms and data dictionaries to standardize measurements and metadata.
5. Plan interim monitoring procedures and ethical stopping criteria and document decision pathways.
6. Publish protocol metadata, SOPs, and amendment history under version control for transparency.
1. 3. Standardize Environment and Minimize Non-specific Stressors
Learning Outcomes:
1. Audit housing environment (light cycles, temperature, humidity, sound) and implement standardization plans with continuous monitoring and alert thresholds.
2. Implement refined handling and habituation regimens to reduce unintended stress and quantify impact on corticosterone/HRV readouts.
3. Validate environmental sensors and telemetry systems for accuracy and reliability and define calibration schedules.
4. Analyze contributions of husbandry variables (cage density, enrichment) to stress biomarkers and adjust protocols to mitigate confounding.
5. Train and certify personnel on standardized handling and monitoring procedures with competency assessments and logs.
6. Report environmental covariates in publications per ARRIVE and incorporate into statistical models as random or fixed effects.
2. Rigorous Design, Interventions, and Correlative Readouts
2. 1. Power, Randomization, and Blinding for Tumor Studies
Learning Outcomes:
1. Estimate sample size using pilot variance and tumor growth kinetics (e.g., Gompertz models) to achieve target power.
2. Implement randomization, allocation concealment, and blinding across handlers, surgeons, and analysts to reduce bias.
3. Design cage-level blocking and account for nesting effects in analysis plans; simulate scenarios to assess impact.
4. Define multiplicity control strategies for multi-endpoint testing (FDR, Bonferroni, hierarchical).
5. Pre-specify covariate adjustments and missing data handling (MI, IPW) in a statistical analysis plan.
6. Generate a reproducible computational notebook for design simulations and parameter justification.
2. 2. GR/β-AR Modulation and Immune Phenotyping
Learning Outcomes:
1. Implement intervention arms (propranolol, mifepristone, CRHR1 antagonists; CRISPRi/a of NR3C1/ADRB2) with dosing, scheduling, and target engagement plans.
2. Quantify tumor burden, metastasis, and survival longitudinally; collect immune infiltration via multicolor flow cytometry and IHC with validated panels.
3. Validate on-target activity via gene expression/phospho-protein assays and, where feasible, PK/PD profiling.
4. Manage dosing adherence, randomization logs, and chain-of-custody for drugs and genetic reagents.
5. Harmonize biospecimen collection for correlative omics (RNA-seq, ATAC-seq) with SOPs and cold-chain integrity.
6. Track adverse events and report per IACUC and institutional policies with escalation pathways.
2. 3. Develop Quantitative Imaging and Digital Pathology Pipelines
Learning Outcomes:
1. Acquire longitudinal imaging (ultrasound, MRI, bioluminescence) with standardized acquisition protocols and phantom calibration.
2. Implement lesion segmentation and volumetry with validated algorithms and assess inter-/intra-rater reliability (ICC) for tumor burden metrics.
3. Automate IHC quantification (e.g., CD8, Ki67) using digital pathology; calibrate thresholds and validate against manual scoring.
3. Analysis, Ethics, and Cross-Model Case Vignettes
3. 1. Analyze Longitudinal Tumor Growth and Multiplicity
Learning Outcomes:
1. Fit mixed-effects or joint models for tumor growth and metastasis including cage and batch random effects and report parameter uncertainty.
2. Adjust for multiplicity across endpoints and interim looks using pre-specified procedures and interpret adjusted effect sizes.
3. Visualize longitudinal trajectories with uncertainty bands and compare intervention effects over time.
4. Conduct sensitivity analyses for missing data, protocol deviations, and outliers with transparent decision logs.
5. Prepare reproducible analysis scripts and blinded re-review summaries for confirmatory validation.
6. Create submission-ready figures and tables consistent with ARRIVE reporting standards.
3. 2. Ensure Ethics Compliance and Generalizability
Learning Outcomes:
1. Audit protocols for IACUC/ARRIVE/PREPARE compliance and animal welfare metrics and implement corrective actions.
2. Develop case vignettes comparing stress paradigms and intervention strategies across at least two tumor models and critique threats to validity.
3. Predefine success criteria and apply graded outcome scales to evaluate intervention efficacy and reproducibility.
4. Assess generalizability by comparing effects across sexes, strains, and housing conditions and quantify heterogeneity.
5. Version-control protocols, data, and analyses with Git/OSF and maintain deviation logs with rationale.
6. Synthesize translational implications and identify gaps to inform next-phase studies.
3. 3. Audit Reproducibility, Data Sharing, and Transparency
Learning Outcomes:
1. Conduct internal reproducibility audits evaluating protocol adherence, data integrity, and analysis traceability with corrective action plans.
2. Prepare OSF/Git repositories containing raw/processed data, metadata, and analysis pipelines with DOIs and clear reuse licenses.
3. Implement blinded reanalysis or independent replication by a separate analyst and compare outcomes with primary analyses.
5. Model gene–environment interactions between chronic stress biomarkers and inherited cancer risk (e.g., BRCA1/2, polygenic risk scores) using robust statistical and causal frameworks in cohort or biobank data.
Learning Targets:
1. Curate and harmonize datasets combining genotype, stress measures (PSS, diurnal cortisol, HRV), and cancer outcomes; perform QC (PLINK, KING), impute genotypes (Minimac4), and address missingness via multiple imputation.
2. Construct and calibrate polygenic risk scores (LDpred2/PRS-CS), standardize scores, and assess discrimination (AUC/C-index) and calibration (e.g., Hosmer–Lemeshow).
3. Fit interaction models (logistic/Cox) with product terms, estimate additive interaction (RERI, AP, S), and adjust for ancestry PCs, batch, and socioeconomic confounders using robust variance estimators.
4. Model time-varying stress using marginal structural models with inverse probability weighting and perform sensitivity analyses for exposure misclassification and selection bias.
5. Conduct Mendelian randomization or MR-GxE with valid HPA-axis instruments where feasible; triangulate with negative controls and compute E-values for unmeasured confounding.
Modules
1. Cohort Harmonization and Polygenic Risk Modeling
1. 1. Genotype QC, Imputation, and Stress Measure Harmonization
Learning Outcomes:
1. Curate cohorts linking genotype, stress measures (PSS, diurnal cortisol, HRV), covariates, and cancer outcomes with standardized data models.
2. Perform genotype QC using PLINK (call rate, HWE, heterozygosity), relatedness estimation (KING), and compute ancestry principal components.
3. Impute genotypes with Minimac4 and document imputation quality (Rsq) and variant inclusion thresholds.
4. Clean and harmonize biomarker data; implement multiple imputation for missingness under MAR assumptions with diagnostics.
5. Standardize variable definitions and coding across datasets; derive harmonized stress composites where appropriate.
6. Register data harmonization and QC protocols with reproducible code and audit trails.
1. 2. Construct and Validate Polygenic Risk Scores
Learning Outcomes:
1. Build PRS using LDpred2 or PRS-CS with ancestry-matched LD panels and cross-validate hyperparameters.
2. Standardize PRS and assess discrimination (AUC/C-index) and calibration (calibration plots, Hosmer–Lemeshow) in internal validation.
3. Evaluate PRS transferability across ancestry groups and recalibrate using shrinkage or reweighting where necessary.
4. Combine PRS with clinical covariates in risk models and assess reclassification (NRI, IDI) and decision-curve utility.
5. Implement fairness diagnostics across demographics (calibration-in-the-large, subgroup AUC) and propose mitigation if needed.
6. Publish PRS weights, evaluation notebooks, and reporting checklists for reproducibility.
1. 3. Implement Privacy-Preserving Linkage and Governance for Biobanks
Learning Outcomes:
1. Design data use agreements and governance frameworks compliant with IRB, HIPAA, and GDPR for multi-institutional GxE studies.
2. Execute privacy-preserving record linkage (e.g., Bloom filters, cryptographic hashing) to join genotype and stress biomarker records without direct identifiers.
3. Apply differential privacy, secure enclaves, or federated analytics to protect participant privacy and evaluate utility–privacy trade-offs.
4. Implement role-based access control, logging, and audit trails for data access and analytic runs across collaborating sites.
5. Conduct disclosure risk assessments and statistical disclosure control for small cells and rare variants and document mitigation actions.
6. Publish governance documentation, data dictionaries, and access workflows to enable transparent, ethical data sharing.
2. Interaction Modeling and Causal GxE Inference
2. 1. Estimate Gene–Stress Interactions in Logistic/Cox Frameworks
Learning Outcomes:
1. Fit logistic and Cox models with gene-by-stress product terms using robust variance estimators and clustered standard errors as needed.
2. Estimate additive interaction metrics (RERI, attributable proportion, synergy index) with confidence intervals and interpret on risk scales.
3. Adjust for ancestry PCs, batch, and socioeconomic confounders and test nonlinearity using splines or transformation.
4. Validate models via internal/external validation and bootstrap optimism correction and assess overfitting risk.
5. Visualize interaction surfaces and marginal effects with partial dependence and contour plots for interpretability.
6. Document model specifications, diagnostics, and decision logs in reproducible notebooks.
2. 2. Model Time-Varying Stress and Apply MR/MR-GxE
Learning Outcomes:
1. Model time-varying stress using marginal structural models with inverse probability weights and assess positivity and weight stability.
2. Conduct sensitivity analyses for exposure misclassification and selection bias using quantitative bias analysis.
3. Implement Mendelian randomization or MR-GxE analyses with valid HPA-axis instruments (e.g., cortisol-related variants) and test assumptions (relevance, independence, exclusion).
4. Triangulate findings with negative control exposures/outcomes and compute E-values for unmeasured confounding.
5. Report instrument strength (F-statistics) and pleiotropy diagnostics (MR-Egger intercept, heterogeneity) to justify causal claims.
6. Release fully reproducible code, synthetic data examples, and analytic checklists for peer scrutiny.
2. 3. Apply Targeted Learning and Doubly Robust Estimation for GxE
Learning Outcomes:
1. Implement Super Learner ensembles for outcome and exposure models to capture nonlinearities and interactions in high-dimensional data.
2. Estimate GxE effects using TMLE or augmented inverse probability weighting and compare performance to maximum likelihood estimators in simulations.
6. Synthesize multi-omics, preclinical, and epidemiologic evidence to prioritize translational targets and propose intervention strategies that mitigate stress-related oncogenic mechanisms, communicating findings effectively to scientific stakeholders.
Learning Targets:
1. Prioritize candidate nodes (GR, β2-AR, NF-κB, STAT3, DNA repair regulators) using network centrality and evidence weighting; query DrugBank, ChEMBL, DGIdb, and Open Targets for druggability and indications.
2. Design a biomarker-enriched, Bayesian adaptive phase II trial of adjunct β-blockade or GR antagonism stratified by stress biomarkers, specifying eligibility, endpoints, interim rules, and correlative biomarker plans.
3. Develop decision-ready visualizations and interactive dashboards (R/Shiny, Python/Plotly) integrating multi-omics, preclinical, and epidemiologic results with full provenance.
4. Evaluate ethical, diversity, and equity considerations in stress and cancer research and propose mitigation strategies for bias and participant burden, including remote monitoring approaches.
5. Conduct multi-omics translational case studies across at least three tumor types (e.g., breast, prostate, pancreatic) using TCGA/ICGC and stress-biomarker cohorts; integrate mechanistic, preclinical, and epidemiologic evidence into decision-ready case briefs and rate certainty using GRADE.
6. Simulate stakeholder decision scenarios with synthetic patient profiles stratified by stress biomarkers and genetic risk; apply Bayesian decision analysis to compare interventions (β-blockade, GR antagonism) under varying priors and utilities and report expected value of information.
Modules
1. Target Prioritization and Druggability Assessment
1. 1. Rank Stress-Responsive Nodes for Translation
Learning Outcomes:
1. Compute network centrality (betweenness, eigenvector) for GR, β2-AR, NF-κB, STAT3, and DNA repair regulators and integrate multi-omics evidence weights.
2. Prioritize targets using multi-criteria decision analysis incorporating effect size, causal support, safety, and feasibility metrics.
3. Query DrugBank, ChEMBL, DGIdb, and Open Targets to enumerate drug–target relationships and clinical indications.
4. Rank candidates by druggability, prior clinical evidence, and mechanism plausibility for stress-linked oncogenesis.
5. Assemble target product profiles detailing MOA, biomarkers, safety signals, and development risks.
6. Present prioritization dashboards and solicit structured feedback from stakeholders to refine rankings.
1. 2. Evaluate Repurposing Opportunities and Readiness
Learning Outcomes:
1. Map repurposable agents (nonselective β-blockers, selective β2 antagonists, GR antagonists) to prioritized nodes and pathways.
2. Evaluate PK/PD properties, BBB permeability, contraindications, and drug–drug interaction risks for candidate interventions.
3. Screen clinical trial registries and RWE sources for prior signals and synthesize evidence strength with GRADE.
4. Propose biomarker-enriched strategies and companion diagnostics aligned with stress biomarkers and TF activity readouts.
5. Draft preclinical-to-clinical translation roadmaps with go/no-go criteria and resource estimates.
6. Assess IP, regulatory pathways, and reimbursement considerations to inform development strategy.
1. 3. Assess Safety, Immunologic Risk, and Off-Target Effects
Learning Outcomes:
1. Compile safety profiles and contraindications from labels and literature and summarize pharmacovigilance signals from FAERS/VigiBase for candidate agents.
2. Analyze immunologic risks and potential interaction with immunotherapy by integrating cytokine, T-cell function, and macrophage polarization evidence.
3. Model benefit–risk trade-offs using multi-criteria decision analysis with stakeholder-weighted utilities and uncertainty bounds.
4. Design focused preclinical toxicology and safety pharmacology bridging aligned with proposed clinical dosing and exposure margins.
5. Define pharmacovigilance strategies and real-world evidence monitoring plans for post-authorization safety tracking.
6. Document safety risk registers and mitigation strategies to inform trial design and patient monitoring.
2. Adaptive Trial Design and Correlative Biomarker Plans
2. 1. Design Bayesian Adaptive Phase II Trials
Learning Outcomes:
1. Specify a Bayesian adaptive phase II design stratified by stress biomarkers with priors, endpoints, and interim decision rules.
2. Simulate operating characteristics (power, type I error, expected sample size) under varying effect sizes and biomarker prevalences.
3. Plan randomization adaptations, cohort expansions, and futility/efficacy stopping guided by posterior probabilities.
4. Integrate safety monitoring plans and DSMB processes into the design and articulate escalation/de-escalation logic.
5. Define analysis frameworks for primary and secondary endpoints with hierarchical modeling where appropriate.
6. Draft a comprehensive statistical analysis plan and charter excerpts for governance.
2. 2. Correlative Biomarker and Data Governance Strategy
4. Produce concise case briefs summarizing target rationale, evidence strength (GRADE), and trial-readiness assessments.
5. Automate report generation with templated pipelines and maintain versioning for iterative updates.
6. Collect stakeholder feedback systematically and iterate visualization designs to improve clarity and impact.
3. 2. Advance Ethics, Diversity, and Bayesian Decision Scenarios
Learning Outcomes:
1. Evaluate ethical, diversity, and equity considerations across study designs and propose mitigation strategies for bias and participant burden.
2. Implement remote monitoring and flexible sampling to increase inclusion while safeguarding data quality and privacy.
3. Simulate stakeholder decision scenarios with synthetic profiles stratified by stress biomarkers and genetic risk levels.
4. Apply Bayesian decision analysis to compare β-blockade vs GR antagonism under varying priors, utilities, and cost constraints.
5. Compute expected value of information to prioritize future studies and refine biomarker thresholds.
6. Document decision processes, assumptions, and rationale in transparent records for governance.
3. 3. Simulate Regulatory and Stakeholder Briefings
Learning Outcomes:
1. Draft regulatory briefing packages aligned with FDA/EMA expectations, including background, rationale, design, and safety risk management.
2. Run mock meetings with clinicians, statisticians, ethicists, and patient partners to elicit questions and required analyses and capture action items.
3. Tailor communication artifacts to diverse audiences (scientific, clinical, patient advocacy) and collect structured usability feedback.
7. Resolve cell-type–specific and spatially organized stress responses within tumors and immune microenvironments using single-cell multi-omics and spatial profiling to map GR/β-adrenergic signaling, ligand–receptor communication, and stress-responsive niches.
Learning Targets:
1. Process and integrate scRNA-seq and scATAC-seq with Seurat/Scanpy/ArchR, correct batch effects (Harmony/LIGER), and annotate cell states with canonical markers and automated classifiers.
2. Infer transcription factor and pathway activities (DoRothEA/VIPER, PROGENy) and GR occupancy surrogates across cell types and validate with GR CUT&Tag in sorted populations.
3. Map ligand–receptor interactions and stress-cytokine networks using CellPhoneDB/NicheNet and prioritize signaling axes altered by stress-hormone exposure.
4. Perform spatial transcriptomics or multiplex imaging (Visium, CosMX, IMC) to localize stress-responsive niches and quantify spatial colocalization and neighborhood enrichment statistics.
5. Integrate single-cell and spatial data to build cell–cell communication graphs and identify candidate intervention points; report robustness across donors and biological replicates.
Modules
1. Single-Cell Data Processing and Annotation
1. 1. Preprocess and Integrate scRNA-seq/scATAC-seq
Learning Outcomes:
1. Process scRNA-seq with Seurat/Scanpy and scATAC-seq with ArchR, applying QC thresholds (UMIs, genes, mitochondrial %) and doublet removal.
2. Integrate datasets using Harmony/LIGER and correct batch effects; evaluate integration with kBET/LISI metrics.
3. Compute embeddings (PCA/UMAP) and identify clusters; annotate with canonical markers and reference-based tools.
4. Implement ambient RNA correction and chromatin accessibility bias controls and document parameter choices.
5. Quantify uncertainty in clustering/annotation via bootstrapping or consensus clustering approaches.
6. Export reproducible object files (h5ad, Seurat RDS) with complete metadata and provenance.
1. 2. Annotate Stress-Responsive Cell States
Learning Outcomes:
1. Train automated classifiers (SingleR, scPred) for cell state annotation and validate against expert-curated labels.
2. Curate stress-responsive states (exhausted T cells, M2 macrophages, CAF subtypes) and define marker panels for each state.
3. Map NR3C1 and ADRB1/2/3 expression across cell types and quantify relative expression changes under stress conditions.
4. Estimate cell-state proportions with uncertainty and compare distributions across stressed versus control samples.
5. Benchmark annotation transfer across datasets/labs and quantify label robustness and drift.
6. Document labeling decision rules and create reproducible annotation pipelines.
1. 3. Optimize Sample Preparation and Batch Mitigation Strategies
Learning Outcomes:
1. Standardize dissociation and nuclei isolation protocols to minimize ex vivo stress artifacts and quantify viability and gene expression perturbations.
2. Compare whole-cell versus nuclei approaches for scATAC-seq and evaluate TSS enrichment, FRiP, and nucleosomal patterns across methods.
3. Implement cell hashing/multiplexing (HTO/CMO) to mitigate batch effects and measure reduction using kBET/LISI and variance decomposition.
4. Monitor ambient RNA and contamination using SoupX/DecontX and document parameter choices and QC thresholds.
5. Plan biological and technical replicate structures and compute variance components to optimize study power and sampling.
6. Record SOPs, QC dashboards, and deviation logs to ensure reproducibility across sites and batches.
2. TF Activity Inference and GR Validation
2. 1. Infer TF/Pathway Activities at Single-Cell Resolution
Learning Outcomes:
1. Infer TF activities using DoRothEA/VIPER and pathway activities with PROGENy across cell types; compute effect sizes and FDR.
2. Estimate GR occupancy surrogates using chromVAR deviations for GR motifs in scATAC-seq and correlate with TF activities.
3. Validate TF activity patterns with GR CUT&Tag in sorted populations and quantify concordance with RNA and ATAC readouts.
4. Model activity drivers using generalized linear mixed models including donor random effects and technical covariates.
5. Compare activity landscapes across tumor compartments and treatments and identify stress-responsive niches.
6. Publish fully parameterized scripts and environment files to reproduce single-cell activity inference.
2. 2. Map Ligand–Receptor Communication Under Stress
Learning Outcomes:
1. Compute ligand–receptor interactions using CellPhoneDB or NicheNet and identify axes altered by stress hormones.
2. Prioritize communication pathways linking tumor, immune, and stromal cells influenced by GR/β-AR signaling.
3. Construct cell–cell communication graphs and compute centrality metrics to identify key sender/receiver populations.
4. Validate predicted interactions using orthogonal data (bulk cytokine assays, flow cytometry) or perturbation datasets.
5. Assess robustness of communication patterns across donors and replicates and quantify heterogeneity.
6. Summarize actionable communication targets for preclinical testing with justification.
2. 3. Leverage Perturb-seq/CROP-seq to Test Stress Pathways
Learning Outcomes:
1. Design CRISPR guide libraries targeting NR3C1, FKBP5, ADRB2, CREB1, and downstream TFs and include controls for on-/off-target assessment.
2. Execute CROP-seq or Perturb-seq in relevant tumor/immune models and link perturbations to single-cell transcriptional and chromatin programs.
3. Analyze perturbation effects using MAST or GLMM frameworks with donor random effects and control FDR across targets and cell states.
3. Spatial Profiling and Integrated Cell–Cell Networks
3. 1. Execute Spatial Transcriptomics/Imaging and Niche Quantification
Learning Outcomes:
1. Generate spatial datasets (Visium, CosMX, IMC) and perform QC, alignment, and image registration with reference standards.
2. Integrate spatial and single-cell references via deconvolution or mapping (Seurat anchors, tangram) and validate mapping accuracy.
3. Localize stress-responsive niches and compute spatial colocalization metrics (Ripley’s K, Moran’s I) with uncertainty.
4. Quantify neighborhood enrichment and interaction distances among cell states under stress versus control conditions.
5. Link spatial niches to GR/β-AR activity surrogates and inflammatory readouts to propose mechanistic microenvironments.
6. Publish annotated spatial maps, segmentation masks, and analysis code with provenance.
3. 2. Integrate Single-Cell and Spatial Data for Intervention Targeting
Learning Outcomes:
1. Integrate single-cell and spatial data into multi-layer communication graphs and identify intervention points sensitive to stress signaling.
2. Evaluate reproducibility of spatial–cellular interactions across biological replicates and donors and quantify variability.
3. Simulate intervention impacts (β-blockade, GR antagonism) on communication networks using network propagation or agent-based models.
4. Prioritize targets for validation based on centrality, spatial proximity to niches, and druggability evidence.
5. Design validation experiments linking spatial hypotheses to preclinical perturbations and define success criteria.
6. Document integration methodologies, limitations, and decision logs for transparent translation.
3. 3. Design Spatial Pharmacodynamics Studies in Stress-Modulated Tumors
Learning Outcomes:
1. Plan pretreatment and on-treatment spatial biopsies or imaging windows to measure GR/β-AR activity surrogates and inflammatory markers in situ.
2. Quantify pharmacodynamic biomarker changes within stress-responsive niches and compute spatial sampling error and confidence intervals.
3. Model spatial biomarker trajectories using mixed-effects geostatistical models accounting for patient and region random effects.
8. Estimate causal pathways by which chronic stress influences cancer incidence or progression through immune, epigenetic, and DNA repair intermediates using counterfactual mediation and targeted learning frameworks.
Learning Targets:
1. Specify causal models with DAGs, identify mediator and confounder sets, and predefine estimands (natural direct/indirect effects) on appropriate scales (risk difference or hazard ratio).
2. Implement mediation analyses using sequential g-estimation, TMLE, or regression-based approaches with sensitivity to mediator–outcome confounding, and quantify proportion mediated with confidence intervals.
3. Address exposure and mediator measurement error with SIMEX or Bayesian measurement models and conduct negative control exposure/outcome analyses to probe hidden bias.
4. Validate causal claims via triangulation by comparing observational mediation with randomized intervention or MR-based mediation where feasible, and document assumption checks and diagnostics.
5. Publish reproducible code and transparent decision records, including model diagnostics, positivity assessments, and sensitivity analyses for unmeasured confounding.
Modules
1. Causal Estimands and DAGs for Stress Pathways
1. 1. Specify DAGs and Mediation Estimands
Learning Outcomes:
1. Draft DAGs encoding pathways from chronic stress to cancer via immune, epigenetic, and DNA repair mediators including confounders and colliders.
2. Identify confounder, mediator, and exposure–mediator interaction structures and justify inclusion/exclusion per causal logic.
3. Define natural direct and indirect effect estimands on risk difference or hazard ratio scales with clear interpretation.
4. State identification conditions (sequential ignorability, no exposure-induced confounding) and align data collection to satisfy them.
5. Predefine sensitivity analyses and diagnostic strategies for assumption violations and model misspecification.
6. Preregister mediation analysis plans, code templates, and data schemas for transparency.
1. 2. Assess Identifiability, Positivity, and Diagnostics
Learning Outcomes:
1. Evaluate positivity, exchangeability, and consistency conditions and design strategies to mitigate violations (trimming, coarsening).
2. Simulate data under hypothesized DAGs to verify identifiability and estimator performance before analyzing real data.
3. Estimate sample size requirements for mediation with multiple mediators and planned covariate adjustments.
4. Define model diagnostics (residuals, calibration, influence) and plan robustness checks for alternative specifications.
5. Specify reporting standards (STROBE/AGReMA) and reproducibility artifacts for mediation analyses.
6. Communicate assumptions, risks, and contingency plans to collaborators to obtain critical review.
1. 3. Select Estimation Strategies and Power Mediation Analyses
Learning Outcomes:
1. Choose mediation estimators (regression-based, sequential g-estimation, TMLE) appropriate to data structure and measurement scales and justify selections a priori.
2. Compute sample sizes and power for multi-mediator analyses using simulation that incorporates anticipated effect sizes, mediator correlations, and measurement error.
3. Predefine modeling of exposure–mediator interactions and nonlinearity using flexible learners and specify interpretation on additive/multiplicative scales.
4. Develop variable measurement protocols and reliability studies to reduce mediator/exposure misclassification and quantify its impact on bias and power.
5. Specify model diagnostics, convergence checks, and stopping rules for iterative estimation workflows and document decision criteria.
6. Prepare parameterized analysis templates and benchmarking datasets to validate pipelines before deployment on real data.
2. Mediation Implementation, Sensitivity, and Triangulation
2. 1. Implement Counterfactual Mediation with TMLE/Sequential G-Estimation
Learning Outcomes:
1. Implement mediation using sequential g-estimation or TMLE with flexible learners (Super Learner) and cross-fitting to reduce bias.
2. Adjust for mediator–outcome confounding and exposure–mediator interactions using appropriate nuisance models.
3. Compute proportions mediated and natural effect estimates with bootstrap confidence intervals and interpret scale dependence.
4. Compare results across regression-based, TMLE, and g-method approaches and perform sensitivity analyses for unmeasured mediator–outcome confounding.
5. Validate causal claims by triangulating with randomized intervention or MR-based mediation where feasible and quantify concordance.
6. Publish end-to-end notebooks with parameter settings, seeds, and diagnostics enabling replication.
2. 2. Address Measurement Error and Probe Hidden Bias
Learning Outcomes:
1. Correct exposure and mediator measurement error using SIMEX or Bayesian measurement models and report posterior uncertainty.
2. Conduct negative control exposure/outcome analyses to probe residual confounding and selection bias.
3. Quantify robustness of findings using E-values and bias formulas under plausible unmeasured confounding scenarios.
4. Triangulate evidence across observational studies, preclinical intervention data, and MR sources to strengthen causal inferences.
5. Compile assumption checks, positivity assessments, and model diagnostics into an auditable decision record.
6. Release reproducible code, synthetic datasets (where needed), and documentation consistent with open science practices.
2. 3. Evaluate Transportability and Generalizability of Mediation Effects
Learning Outcomes:
1. Define target populations and transport mediation effects using weighting or outcome modeling approaches; document assumptions and diagnostics.
2. Assess between-study or site-level heterogeneity in mediated effects using random-effects meta-analysis or hierarchical mediation models.
4. Construct multi-omic regulatory models combining accessibility, methylation, GR binding, 3D contacts, and QTL evidence and assess predictive performance.
5. Validate predicted enhancer–gene pairs with CRISPRi/a perturbations or reporter assays and define quantitative success criteria (effect size, FDR).
6. Visualize integrated regulatory architectures with arc diagrams and track plots and annotate evidence sources and confidence.
5. Publish benchmarking datasets, protocols, and results with FAIR metadata in public repositories and invite external replication.
6. Synthesize best-practice recommendations based on benchmarking outcomes and document limitations and open questions.
4. Characterize cell-cycle distributions and apoptosis using EdU/PI and Annexin V and incorporate as covariates/confounders in analyses.
5. Combine targeted phospho-proteomics with pathway activity scores to map stress-induced DDR reprogramming and benchmark against controls.
6. Document DDR assay SOPs, QC thresholds, and troubleshooting guides for reproducibility across laboratories.
4. Compare temporal trajectories of mutational signatures and HRD metrics between stressed and control lines and test for trends via segmented regression.
5. Quantify fitness effects (growth rates, competition assays) and associate with genomic instability markers and signature exposures.
6. Deposit time-series variant and metadata with complete provenance and analysis notebooks enabling external reanalysis.
4. Link imaging and pathology phenotypes to longitudinal growth/metastasis outcomes using joint or mixed-effects models with uncertainty quantification.
5. Build reproducible image analysis pipelines (Nextflow/Snakemake, Docker) and archive raw images, masks, and code with checksums.
6. Register imaging endpoints and analysis steps in the SAP with pre-specified multiplicity control for correlative endpoints.
4. Create de-identified, analysis-ready datasets for external sharing and ensure compliance with institutional and sponsor requirements.
5. Summarize reproducibility indicators (preregistration, blinding, data availability) and propose improvements for future studies.
6. Draft a transparency and data-sharing statement aligned with ARRIVE/NIH policies for inclusion in manuscripts and reports.
3. Conduct stability selection or elastic net screening for interaction terms while controlling false discovery under correlation.
4. Calibrate and validate interaction models with nested cross-validation and evaluate calibration curves and Brier scores.
5. Visualize heterogeneous interaction effects with partial dependence, ICE plots, and SHAP values while guarding against extrapolation.
6. Publish end-to-end pipelines, simulation code, and documentation enabling replication and extension by external researchers.
5. Establish DSMB charters, safety reporting workflows, and escalation procedures aligned with regulatory guidance.
6. Finalize startup timelines, critical path milestones, and contingency plans to ensure on-time activation and accrual.
4. Iterate dashboard narratives and data visualizations for clarity and decision salience and maintain change logs for governance.
5. Prepare decision memos summarizing options, trade-offs, and expected value of information to guide go/no-go calls.
6. Archive briefing materials, Q&A logs, and rationale to support institutional memory and future submissions.
4. Validate perturbation efficiency and directionality with targeted sequencing and protein assays and include non-targeting and rescue controls.
5. Infer causal flow from receptor perturbations to TF activity and cytokine outputs using mediation or dynamic models at single-cell resolution.
6. Publish guide sequences, libraries, and fully reproducible analysis pipelines to enable replication.
4. Link spatial PD shifts to systemic stress biomarkers (cortisol, HRV) and clinical outcomes to evaluate mechanism engagement.
5. Simulate sample size and power for spatial endpoints under varying effect sizes, spatial autocorrelation, and measurement error.
6. Integrate spatial PD plans with trial correlative workflows and document SOPs, QC, and data governance for clinical deployment.
3. Perform sensitivity analyses for transportability assumptions (positivity, effect modification) and evaluate impact on direct/indirect effects.
4. Compare mediated effects across key subgroups (sex, ancestry, tumor type) and model interaction-in-mediation with appropriate variance estimators.
5. Report generalizability considerations following STROBE and AGReMA extensions and propose strategies for broader applicability.
6. Publish code, vignettes, and case studies demonstrating transportability workflows using open datasets.
